Received: 27 May 2022 | Accepted: 27 May 2022

DOI: 10.1002/rth2.12747

rpth research & practice in thrombosis & haemostasis

ILLUSTRATED REVIEW

Illustrated State-of-the-Art Capsules of the ISTH 2022 Congress

Robert A. Ariëns PhD[1] | Beverley J. Hunt MD OBE[2] | Ejaife O. Agbani BPharm, MSc, PhD[3] | Josefin Ahnström PhD[4] | Robert Ahrends PhD[5] | Raza Alikhan MD, FRCP, FRCPath[6] | Alice Assinger PhD[7] | Zsuzsa Bagoly MD, PhD[8] | Alessandra Balduini MD[9] | Elena Barbon PhD[10] | Christopher D. Barrett MD[11,12,13] | Paul Batty MBBS, PhD[14] | Jorge David Aivazoglou Carneiro MD, PhD[15] | Wee Shian Chan MD, MSc, FRCP[16] | Moniek de Maat PhD[17] | Kerstin de Wit MBChB, MD, MSc[18] | Cécile Denis PhD[19] | Martin H. Ellis MD[20] | Renee Eslick BMed, FRACP, FRCPA[21] | Hongxia Fu PhD[22] | Catherine P. M. Hayward MD, PhD[23] | Benoit Ho-Tin-Noé PhD[24] | Frederikus A. Klok MD, PhD[25] | Riten Kumar MD, MSc[26] | Karin Leiderman PhD[27] | Rustem I. Litvinov MD, PhD[28] | Nigel Mackman PhD[29] | Zoe McQuilten MBBS, PhD[30] | Matthew D. Neal MD[31] | William A. E. Parker MB, PhD, MRCP[32] | Roger J. S. Preston PhD[33] | Julie Rayes PhD[34] | Alireza R. Rezaie PhD[35] | Lara N. Roberts MBBS, MD Res[36] | Bianca Rocca MD, PhD[37] | Susan Shapiro MD, PhD[38,39] | Deborah M. Siegal MD, MSc, FRCPC[40] | Lirlândia P. Sousa PhD[41] | Katsue Suzuki-Inoue MD, PhD[42] | Tahira Zafar MB, DCP, FRCPath[43,44] | Jiaxi Zhou PhD[45]

[1]University of Leeds, Leeds, UK

[2]King's Healthcare Partners, London, UK

[3]Department of Physiology and Pharmacology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada

[4]Centre for Haematology, Imperial College London, London, UK

[5]Institute of Analytical Chemistry, University of Vienna, Vienna, Austria

[6]Haemostasis & Thrombosis, University Hospital of Wales, Cardiff, UK

[7]Medical University of Vienna, Vienna, Austria

[8]Faculty of Medicine, Department of Laboratory Medicine, Division of Clinical Laboratory Sciences and ELKH-DE Neurodegenerative and Cerebrovascular Research Group, University of Debrecen, Debrecen, Hungary

[9]University of Pavia, Pavia, Italy

[10]San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy

[11]Division of Acute Care Surgery and Surgical Critical Care, Department of Surgery, University of Nebraska Medical Center, Omaha, Nebraska, USA

[12]Koch Institute, Center for Precision Cancer Medicine, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA

[13]Division of Surgical Critical Care, Department of Surgery, Boston University Medical Center, Boston University School of Medicine, Boston, Massachusetts, USA

[14]Royal Free Hospital, London, UK

[15]Instituto da Criança do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
[16]University of British Columbia, Vancouver, British Columbia, Canada
[17]Department of Hematology, Erasmus MC, Rotterdam, The Netherlands
[18]Queen's University and McMaster University, Kingston, ON, Canada
[19]INSERM UMRS 1176, Le Kremlin-Bicetre Cedex, France
[20]Hematology Institute and Blood Bank, Meir Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
[21]Haematology Department, Canberra Hospital, Garran, Australian Capital Territory, Australia
[22]Division of Hematology, Department of Medicine, University of Washington, Seattle, Washington, USA
[23]Hamilton Health Sciences, McMaster University Medical Center, Hamilton, Ontario, Canada
[24]INSERM Unit 1148, Paris, France
[25]Department of Medicine – Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands
[26]Dana Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts, USA
[27]Colorado School of Mines, Golden, Colorado, USA
[28]Department of Cell and Developmental Biology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
[29]UNC Blood Research Center, Division of Hematology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
[30]Monash University, Melbourne, Victoria, Australia
[31]Trauma and Transfusion Medicine Research Center, Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
[32]Cardiovascular Research Unit, Northern General Hospital, University of Sheffield, Sheffield, UK
[33]Irish Centre for Vascular Biology, Department of Pharmacy & Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin 2, Ireland
[34]University of Birmingham, Birmingham, UK
[35]Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA
[36]King's Thrombosis Centre, Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, London, UK
[37]Department of Safety and Bioethics, Section of Pharmacology, Catholic University School of Medicine, Rome, Italy
[38]Oxford University Hospitals NHS Foundation Trust, Oxford, UK
[39]Radcliffe Department of Medicine, Oxford University, Oxford, UK
[40]Ottawa Hospital Research Institute and University of Ottawa, Ottawa, Ontario, Canada
[41]Departamento de Análises Clínicas e Toxicológicas, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
[42]Department of Clinical and Laboratory Medicine, University of Yamanashi, Yamanashi, Japan
[43]Frontier Medical College, Abbotabad, Pakistan
[44]Hemophilia Treatment Center, Rawalpindi, Pakistan
[45]Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China

Handling Editor: Dr Michelle Sholzberg

Abstract

The ISTH London 2022 Congress is the first held (mostly) face-to-face again since the COVID-19 pandemic took the world by surprise in 2020. For 2 years we met virtually, but this year's in-person format will allow the ever-so-important and quintessential creativity and networking to flow again. What a pleasure and joy to be able to see everyone! Importantly, all conference proceedings are also streamed (and available recorded) online for those unable to travel on this occasion. This ensures no one misses out. The 2022 scientific program highlights new developments in hemophilia and its treatment, acquired and other inherited bleeding disorders, thromboinflammation, platelets and coagulation, clot structure and composition, fibrinolysis, vascular biology, venous thromboembolism, women's health, arterial thrombosis, pediatrics, COVID-related thrombosis, vaccine-induced thrombocytopenia with thrombosis, and omics and diagnostics. These areas are elegantly reviewed in this Illustrated Review article. The Illustrated Review is a highlight of the ISTH Congress. The format lends itself very well to explaining the science, and the collection of beautiful graphical summaries of recent developments in the field are stunning and self-explanatory. This clever and effective way to communicate research is revolutionary and different from traditional formats. We hope you enjoy this article and will be inspired by its content to generate new research ideas.

CONTENTS

Preeclampsia and platelet procoagulant membrane dynamics

Ejaife O. Agbani BPharm, MSc, PhD



Protein S, tissue factor pathway inhibitor, & factor V

Josefin Ahnström PhD



The initiation phase of coagulation is regulated by tissue factor pathway inhibitor (TFPI), which efficiently reduces/delays thrombin generation. In contrast to the endothelium-bound TFPIβ, which in itself is an effective regulator of coagulation, the soluble form, TFPIα, is completely dependent on cofactors (compare the top and bottom figures for the absence and presence of cofactors, respectively).[1] Protein S enhances the anticoagulant properties of TFPIα through a direct protein-protein interaction, involving specific amino acid residues in TFPIα Kunitz 3 and protein S laminin G-type 1.[1,2] This interaction enables TFPIα to interact with and inhibit membrane-bound factor Xa more efficiently. A splice variant of factor V (FV), FV-short, regulates TFPIα levels through a high-affinity interaction, likely resulting in an increased half-life, as well as functioning as a synergistic TFPIα cofactor, together with protein S.[1,3]

Probing the membrane landscape and identifying key lipids critical for platelet activation by lipidomics

Robert Ahrends PhD



Comprehensive membrane, dietary, and signaling lipidomics to analyze platelet functions.

(A) Platelet purification from mice and human models, ex vivo stimulation using different stimuli and subsequent lipidomics workflow with data integration. (B) Lipid mediator precursor level of LPI, PI and AA in resting or with thrombin- (Thr) or collagen-related peptide (CRP)- activated human platelets. (B lower panel) Derived intracellular lipid mediator concentrations (square bars) and secreted lipid mediator levels (triangle bars) in resting and activated state. (C) Network visualization of the lipid-lipid correlation between resting and Thr or CRP-stimulated human platelets.

For references, see Peng et al.[4,5]; Holinstat[6]

Cancer associated thrombosis: What the guidelines say and what they do not say

Raza Alikhan MD, FRCP, FRCPath



Platelet-leukocyte interaction: Detection and functional relevance in infection and sterile inflammation

Alice Assinger PhD



Monitoring efficacy of fibrinolysis in stroke

Zsuzsa Bagoly MD, PhD



Currently, there are two proven reperfusion strategies for the opening of the occluded vessel in patients with acute ischemic stroke (AIS): intravenous thrombolysis using recombinant tissue-type plasminogen activator (rt-PA; alteplase) or tenecteplase, and mechanical thrombectomy.[7] Both therapies must be delivered within a rapid time frame in selected patients; moreover, mechanical thrombectomy is eligible in only a fraction of patients with large-artery occlusion. Despite the unquestionable effectiveness of rt-PA as first-line treatment of AIS, successful reperfusion is achieved in only ≈30% to 40% of patients, while ≈6% to 8% of patients develop intracranial hemorrhage as a side effect. As of today, outcomes cannot be foreseen at the initiation of therapy, and this remains one of the greatest challenges of AIS treatment.[8] Due to the short time frame before treatment, few studies are available on hemostasis tests, and several methodological issues are raised.[8,9] Nevertheless, some assays show promising results and need to be further investigated and validated in large populations.

Megakaryocytes and different thrombopoietic environments

Alessandra Balduini MD



Circulating platelets are specialized cells produced by megakaryocytes through the formation of proplatelets. Leading studies point to the bone marrow niche as the core of hematopoietic stem cell (HSC) differentiation, revealing interesting and complex environmental factors for consideration. Megakaryocytes take cues from the physicochemical bone marrow microenvironment, which includes contact with extracellular matrix components, interaction with endothelium, and contact with the turbulent flow generated by the blood circulation into the sinusoid lumen.[10] Germinal and acquired mutation in HSCs may manifest in altered megakaryocyte maturation, proliferation, and platelet production. Alterations of the whole hematopoietic niche may also occur, highlighting the central role of megakaryocytes in the control of the physiological bone marrow homeostasis. Tissue-engineering approaches have been developed to create a functional mimic of the native tissue.[11,12] Reproducing the thrombopoietic environment is instrumental to gaining new insight into its activity and answering the growing demand for human platelets for fundamental studies and clinical applications in transfusion medicine. (ECM, extracellular matrix; MK, megakaryocyte; iPSC, induced pluripotent stem cell; MSC, mesenchymal stem cell; PPF, proplatelet formation; PLT, platelet; TPO, thrombopoietin; TGFβ, transforming growth factor-β).

The figure was created with BioRender.com

Engineering of adeno-associated viruses to enhance cell-specific transduction

Elena Barbon PhD



Adeno-associated viral vectors have emerged as one of the most promising gene delivery platforms for in vivo liver-directed gene therapy for the treatment of blood coagulation disorders, particularly hemophilia A (HA) and B (HB). The ongoing clinical trials are based on adeno-associated virus (AAV)-mediated hepatocyte-targeted expression of coagulation factor VIII or IX for HA and HB, respectively.[13] Nevertheless, there is increasing interest in the possibility of improving the targeting of different cell types. To this aim, AAV capsid engineering represents an attractive strategy to enhance cell-specific transduction.[14,15] This may represent a promising approach in coagulation diseases such as HA or von Willebrand disease, where expressing the therapeutic protein from its natural biosynthetic site, that is, endothelial cells, could be beneficial to guarantee an optimized protein biosynthesis, secretion, and activity.

Fibrinolysis and thrombolytic therapy in COVID-19 respiratory failure

Christopher D. Barrett MD



For references, see Barrett et al.[16,17]; ATTACC Investigators et al.[18]

Adeno-associated virus integration

Paul Batty MBBS, PhD



Update on the pathogenesis of COVID-19 and multisystem inflammatory syndrome in children

Jorge David Aivazoglou Carneiro MD, PhD



Pathogenesis of COVID-19 and multisystem inflammatory syndromein children (MIS-C)

1. Severe acute respiratory syndrome coronavirus 2 infection affects several body organs in special respiratory, cardiovascular, gastrointestinal, and nervous systems, causing direct tissue damage.
2. Innate immune system activation is the first step of host immune response initiating inflammatory pathways that provide viral clearance. However, an innate immune response out of control may result in severe COVID-19 or MIS-C.
3. The endothelium plays an important role in the balance of hemostasis. Therefore, endothelial damage and inflammation promote a hypercoagulable state and thrombosis.

For references, see Yuki et al.[19]; Gustine and Jones[20]; Diamond and Kanneganti[21]

Can pregnancy-adapted algorithms rule out venous thromboembolism in pregnancy?

Wee Shian Chan MD, MSc, FRCP



For references, see Konstantinides et al.[22]; van der Pol et al.[23]; Righini et al.[24]

Biomarkers for stroke prediction

Moniek de Maat PhD



	ischemic stroke risk in healthy population	outcome after stroke	outcome after tPA treatment
Primary hemostasis			
von Willlebrand factor	↑	-/↑	-
ADAMTS13	↓	-/↓	↓
platelet activation markers	-/↑	-/↑	no data
Secondary hemostasis			
fibrinogen	↑	-/↑	-
FVIII	↑	-/↑	-
thrombin generation	↓↑	no data	no data
Fibrinolysis			
PAI-1	-	-/↑	-/↑
clot lysis time	no data	no data	↓
D-dimer	↑	↑	no data
Thrombus characteristics			
mechanical, fibrin network	no data	no data	no data
Inflammation			
C-reactive protein, cytokines	↑	no data	no data
Immunothrombosis			
NETs, eDNA	no data	no data	↓

Risk stratification for acute venous thromboembolism

Kerstin de Wit MBChB, MD, MSc



Patients with acute pulmonary embolism (PE) can be classified as having low-risk PE (75% of cases), intermediate-risk PE (20% of cases), or high-risk PE (5% of cases). Low-risk patients can be assessed for outpatient treatment with rapid follow-up. Intermediate-risk patients are admitted for monitoring, and high-risk patients require immediate reperfusion therapy.[22]

PESI, pulmonary embolism severity index; VTE, venous thromboembolism.

New animal models for bleeding disorders and treatments

Cécile Denis PhD



FVIII, factor VIII; VWD, von Willebrand disease; VWF, von Willebrand factor.

Myeloproliferative neoplasms in pregnancy: Implications for mother and child

Martin H. Ellis MD

MPN in pregnancy: Incidence

3.2 per 100 00 pregnancies per year

Pregnancy-related complications are common in MPN

Pregnancy loss=28.7%

Adverse outcomes* =9.8%

*VTE, ATE, preeclampsia, abruption, IUGR



MPN in pregnancy: Treatment recommendations

First pregnancy

Maternal VTE /ATE prophylaxis

- LMWH (VTE)
  (Only for co-existent VTE risk factors: previous VTE, C/S, advanced age, obesity)
- Aspirin (ATE)

Placenta-related prophylaxis

- Observation or aspirin

Subsequent pregnancies

(in case of previous placenta-related complications)

Maternal VTE/ATE prophylaxis

- As for first pregnancy

Placenta-related prophylaxis

- Interferon
- Aspirin-low dose

MPN=myeloproliferative neoplasm IUGR=Intrauterine growth restriction
VTE=venous thromboembolism ATE=arterial thromboembolism C/S=Cesarean section LMWH=low molecular weight heparin

Polycythemia vera, essential thrombocythemia, and primary myelofibrosis (termed *myeloproliferative neoplasms* [MPNs]) are clonal diseases that may result in fatal end-stage bone marrow fibrosis or acute leukemia. During the long natural history of these diseases, thrombosis is an important complication.

The median age at diagnosis of the MPNs is >60 years; however, 20% of patients are <40 years old when diagnosed, making MPNs in pregnancy a relevant clinical issue. Indeed, the estimated incidence of MPNs among pregnant women in the United Kingdom is 3.2 in 100 000 pregnancies per year.[25]

The risk of maternal (venous or arterial thrombosis or hemorrhage), or placenta-related (fetal loss or preeclampsia/eclampsia) complications is higher in pregnancies in patients with MPNs than in the general population. Meta-analysis data demonstrate that 28.7% pregnancies are lost among these patients and that an additional 9.6% of women experience an adverse outcome such as thrombosis, preeclampsia, eclampsia, placental abruption, or intrauterine growth retardation.[26]

Treatment is based on observational data and expert opinion and includes aspirin, low-molecular-weight heparin, and interferon-α. Prospective studies are needed to better define appropriate treatment for these patients.

Management of thrombocytopenia in pregnancy

Renee Eslick BMed, FRACP, FRCPA



IVIg, intravenous immunoglobulin; ITP, immune thrombocytopenia; PET, preeclampsia.

For reference, see Eslick et al.[27]

Binding of flow-activated von Willebrand factor to glycoprotein Ib

Hongxia Fu PhD



Blood protein von Willebrand factor (VWF; green) is essential in thrombosis and hemostasis. Force induced by blood flow is an important regulator to mediate VWF hemostatic function. Dynamic single-molecule imaging in a microfluidic system reveals that a two-step conformational transition induces VWF activation mechanism.[28,29] First, VWF elongates from compact to linear form. Second, a tension above 21 pN (dark green shading) induces VWF transition to a state with high affinity for platelet glycoprotein Ibα (GPIbα; magenta). For clarity, platelets are not shown. GPIbα dissociates rapidly when tension is under 21 pN. This mechanism allows VWF to be activated by hydrodynamic force at sites of hemorrhage but avoid thrombus formation downstream. (Single-molecule fluorescence images were reproduced from Fu et al.,[28] *Nature Communications*, 2017 with modifications and shared via a Creative Commons 4.0 license.)

Hemostatic defects in fibrinolytic disorders

Catherine P. M. Hayward MD, PhD



Thrombus composition and thrombolysis resistance in stroke

Benoit Ho-Tin-Noé PhD



The introduction of mechanical thrombectomy has considerably increased the rate of successful recanalization in large-vessel occlusion stroke. From a basic research standpoint, it has enabled the analysis of stroke thrombi and a better understanding of the mechanisms underlying resistance to intravenous thrombolysis. Therefore, although the efficacy of mechanical thrombectomy could have caused the end of thrombolysis, it has instead opened the way for its rethinking and improvement, through the development of innovative thrombolytic strategies.

Outcomes of venous thromboembolism

Frederikus A. Klok MD, PhD



VTE: Venous thromboembolism, **PTS:** post-thrombotic syndrome, **PPES:** Post pulmonary embolism syndrome, **CTEPH:** Chronic thromboembolic pulmonary hypertension, **CTEPD:** Chronic thromboembolic pulmonary disease, **PTSD:** Post-traumatic stress syndrome, a mental or behavioural response from the trauma of experiencing a VTE, **ADLS:** Activities of daily living.

Multisystem inflammatory syndrome in children and thrombotic complications of COVID-19 in children

Riten Kumar MD, MSc



ACR, American College of Rheumatology; ACTION, Advanced Cardiac Therapies Improving Outcomes Network; anti-FXa, anti–factor Xa; CAA, coronary artery aneurysm; CVL, central venous line; DOAC, direct oral anticoagulant; DTI, direct thrombin inhibitor; ECG, electrocardiogram; LMWH, low-molecular-weight heparin; LV, left ventricular; MA, maximum amplitude; TEG, thromboelastogram; UFH, unfractionated heparin; ULN, upper limit of normal; VKA, vitamin K antagonist; VTE, venous thromboembolism

For references, see Goldenberg et al.[30]; Henderson et al.[31]; Bansal et al.[32]

Mathematical modeling to study variability in bleeding

Karin Leiderman PhD



Blood clot contraction: Mechanisms, pathophysiology, and disease

Rustem I. Litvinov MD, PhD



Contraction (retraction) of blood clots and thrombi is clinically important since it can affect their obstructiveness, permeability, susceptibility to fibrinolysis, and the propensity to rupture (embologenicity). The rate and extent of clot contraction in vitro and in vivo can be enhanced or inhibited by altered platelet functionality as well as pathological cellular and molecular composition of the blood.[33] Clot contraction is reduced in the blood of patients with various (pro)thrombotic conditions, due to continuous platelet activation followed by their exhaustion and reduced contractility.[34] Impaired clot contraction is a significant but understudied and underappreciated pathogenic factor that can influence the course and outcomes of thrombotic disorders.[35]

Mechanisms of cancer-associated thrombosis

Nigel Mackman PhD



The majority of studies on the mechanisms of cancer-associated thrombosis (CAT) have focused on pancreatic cancer and brain cancer because they have the highest rates of venous thromboembolism (VTE). There are several pathways that contribute to venous thrombosis in pancreatic and brain cancer. Human studies have identified circulating biomarkers that are associated with VTE. Mouse cancer models are used to directly examine the role of a pathway in venous thrombosis. Taken together, these studies suggest that tissue factor–positive extracellular vesicles (EVs) directly and indirectly (via activation of platelets) enhance venous thrombosis in both pancreatic and brain cancer.[36,37] Neutrophils form neutrophil extracellular traps that can enhance venous thrombosis in pancreatic cancer.[36] Plasminogen activator inhibitor-1 contributes to venous thrombosis in pancreatic cancer by inhibiting fibrinolysis.[38] In brain cancer, podoplanin-positive EVs activate platelets and enhance venous thrombosis.[37] Targeting these pathways may reduce CAT.

Image created with BioRender.com

When to use tranexamic acid in bleeding

Zoe McQuilten MBBS, PhD

SUMMARY OF RANDOMIZED CONTROLLED TRIALS OF TRANEXAMIC ACID FOR BLEEDING

CLINICAL SITUATION	RCT#	TRANEXAMIC ACID: DOSE (IV)*	MORTALITY	OTHER	EVIDENCE TO SUPPORT USE?: THROMBO-EMBOLISM	SEIZURES	
TRAUMATIC HEMORRHAGE	5	Loading: 1g/10 min Infusion: 1g/8 hr vs. placebo	EVIDENCE OF BENEFIT		NO DIFFERENCE	NO DIFFERENCE	YES, best if given within 3 hrs
TRAUMATIC BRAIN INJURY	9	Loading: 1g/10 min Infusion: 1g/8 hr vs. placebo	EVIDENCE OF BENEFIT if given <3hrs of mild-moderate injury	Possibly reduced hematoma expansion	NO DIFFERENCE	NO DIFFERENCE	MAYBE, if given to mild-moderate TBI within 3 hrs
SPONTANEOUS INTRACEREBRAL HEMORRHAGE	4	Loading : 1g Infusion: 1g/8 hr vs. placebo	NO EVIDENCE OF BENEFIT	Reduced hematoma expansion	NO DIFFERENCE	NO DIFFERENCE	NO, further research needed
POSTPARTUM HEMORRHAGE	2	1g + 1g if bleeding after 30 min or stopped and restarted within 24hrs, vs. placebo	EVIDENCE OF REDUCTION IN DEATH due to bleeding	No change in hysterectomy or transfusion rates	NO DIFFERENCE	NO DIFFERENCE	YES, best if given within 3 hrs of birth
GASTRO-INTESTINAL HEMORRHAGE	5	Loading Dose: 1g Infusion: 3g/24 hrs vs. placebo	NO EVIDENCE OF BENEFIT		HIGHER RISK OF VENOUS THROMBO-EMBOLISM	HIGHER RISK	NO

*STUDIED IN LARGEST TRIAL

Platelet and endothelial biology in bleeding

Matthew D. Neal MD



Following trauma and hemorrhage, the systemic signals of hypoxia, danger-associated molecular patterns and cytokines produce endothelial injury in addition to direct endothelial disruption.[39] The platelet is the sentinel responder to injury, orchestrating the complex processes of hemostasis and coagulation through interaction with damaged endothelium.[40] This State of the Art will review the adaptive and maladaptive responses of platelets and endothelium to bleeding with a focus on key mediators including von Willebrand factor, the metalloprotease ADAMTS-13,[41] neutrophil extracellular trap release, and the role of endothelial and platelet extracellular vesicles in cell signaling.

Drug therapy for stroke prevention

William A. E. Parker MB, PhD, MRCP



Drugs for control of modifiable risk factors in the prevention of stroke. Modified with permission from Parker et al. 2020 under Creative Commons CC-BY-NC license.[42] CKD, chronic kidney disease; DAPT, dual antiplatelet therapy; DATT, dual antithrombotic therapy; GLP-1, glucagonlike peptide 1; HbA_{1c}, glycated hemoglobin; LDL-C, low-density lipoprotein cholesterol; LEAD, lower-extremity arterial disease; NOAC, non–vitamin-K antagonist oral anticoagulant; OAC, oral anticoagulant; PCSK9, proprotein convertase subtilisin/kexin type 9; RASi, renin-angiotensinsystem inhibitor; SAPT, single antiplatelet therapy; T2DM, type 2 diabetes mellitus; VKA, vitamin K antagonist.

Coagulation factor signaling

Roger J. S. Preston PhD



Most coagulation factor cell signaling is mediated by protease-activated receptors (PARs), a unique family of G-protein–coupled receptors whose activation is triggered by receptor proteolysis. Cell signaling output arising from PAR activation is shaped by both the activating protease and the specific cellular contexts in which receptor activation has occurred. Although not yet fully understood, intra- and extracellular regulatory determinants of PAR signaling diversity include protease-specific cleavage sites, association with protease coreceptors, receptor oligomerization, and recruitment of distinct signaling intermediates. These mechanisms combine to enable coagulation proteases to initiate a spectrum of downstream signaling pathways in multiple cell types.

Novel mechanisms of thromboinflammation during infection and hemolysis

Julie Rayes PhD



- S100A8/A9 is a damage-associated molecular pattern with prothrombotic and proinflammatory properties.
- S100A8/A9 levels are increased in the plasma of patients with COVID-19.
- Deposition of S100A8/A9 on the vessel wall in patients with COVID-19 correlates with thrombotic complications.
- S100A8/A9 induces the formation of procoagulant platelets and amplifies fibrin generation.
- Glycoprotein Ibα is the main receptor for S100A8/A9 on platelets, with a supporting role for CD36.

Thrombomodulin regulates endothelial quiescence

Alireza R. Rezaie PhD



(A)

1. Thrombomodulin (TM), endothelial protein C receptor (EPCR), and protease-activated receptor-1 (PAR1), are colocalized in lipid rafts of endothelial cells.
2. Thrombin binds TM and activates EPCR-bound protein C.
3. Activated protein C (APC) in association with EPCR functions in the anti-inflammatory pathway by activating PAR1 and inducing cytoprotective b-arrestin-2 biased signaling.
4. APC functions in the anticoagulant pathway by binding protein S and inactivating factors Va and VIIIa (FVi/FVIIIi).

(B)

1. TM has anti-inflammatory and barrier-stabilizing functions and extracellular signal-regulated and nuclear factor kappa-light-chain-enhancer of activated B cells signaling.
2. (Pro)exosite-1 of (pro)thrombin binds epidermal growth factor (EGF)-like domains of TM and induces cytoprotective signaling.
3. Cytoplasmic domain of TM is involved in recruiting phosphatase and tensin homolog to plasma membrane, thereby regulating endothelial cell proliferation, angiogenesis, and metabolism through PI3K/AKT/FOXO1/mTOR signaling.
4. TM knockdown or deletion of its cytoplasmic-domain leads to barrier destabilization, constitutive expression/secretion of von Willebrand factor (VWF), cell surface platelet-VWF strings formation, reduced angiopoietin 2 expression and deregulated endothelial cell proliferation, angiogenesis and Tie2 receptor signaling. (Pro)Th, (pro)thrombin; WPB, Weibel Palade body.

Systematic approach to venous thromboembolism prevention

Lara N. Roberts MBBS, MD Res



Created with BioRender.com

VTE, venous thromboembolism.

For references, see Roberts et al.[43]; NHS Digital[44]

Personalizing antiplatelet therapy based on platelet turnover and metabolic phenotype

Bianca Rocca MD, PhD



Variability in the response to fixed-dose antiplatelet drugs can be increased by primary (essential thrombocythemia) or secondary (reactive inflammatory states) pathological conditions associated with increased platelet turnover and count, that is, pharmacodynamic (PD) variability, as well as by high-degree obesity, that is, pharmacokinetic (PK) variability.

Understanding PK- and/or PD-related mechanisms of variability is central to design personalized regimens and to optimize the risk/benefit balance of common antiplatelet drugs by increasing the daily frequency or the once-daily dosing.

Moreover, in silico PK/PD modeling and in silico trials can be instrumental in designing clinical trials, developing antithrombotic therapy, and generating new personalized drug regimens.

Finally, in silico PK/PD modelling can be essential in rare diseases and "special" populations such as extreme ages (elderly and children), extreme body sizes (underweight and high-degree obesity), severe comorbidities (severe kidney and liver dysfunction), which are either un-derrepresented or excluded from cardiovascular randomized trials.

A, acetylsalicylic acid; MK, megakaryocyte; od, once daily; P, placebo; TXB_2, thromboxane B_2.

For references, see Tosetto et al.[45]; Rocca et al.[46]; Petrucci et al.[47]

VTE prevention—What have we learned from COVID-19?

Susan Shapiro MD, PhD



Restarting anticoagulants after major bleeding

Deborah M. Siegal MD, MSc, FRCPC



For reference, see Xu and Siegal[48]

The plasminogen/plasmin system beyond fibrinolysis: Emerging players in resolution of inflammation

Lirlândia P. Sousa PhD



The plasminogen/plasmin (Plg/Pla) system is associated with a variety of biological activities beyond the classical dissolution of fibrin clots, including cell migration, tissue repair, and inflammation. Inflammation is an evolutionarily conserved response that guarantees the maintenance of tissue homeostasis through resolution—an active process mediated by molecules named proresolving mediators.[49] Despite the classical view of the Plg/Pla system on inflammation, emerging studies from our group[50,51] and others have revealed its anti-inflammatory and proresolving actions that includes reduction of proinflammatory mediators (1) enhanced neutrophil apoptosis (2), and efferocytosis (3); promotion of nonphlogistic recruitment of mononuclear cells (4); induction of macrophage reprogramming toward resolving phenotypes (5); and induction of expression of the proresolving mediator annexin A1 (6). We have now identified a novel proresolving feature of Plg/Pla during sepsis that is the regulation of neutrophil extracellular trap release (7). Red question marks indicate specific processes that Pla-protease activity need to be covered.

Crosstalk between hemostasis and lymphangiogenesis

Katsue Suzuki-Inoue MD, PhD



Raising awareness of women's bleeding/health issues in culturally challenging settings

Tahira Zafar MB, DCP, FRCPath



For references, see Ali[52]; Butt[53]; UN.[54]

Megakaryocyte single-cell transcriptomics

Jiaxi Zhou PhD



EC, endothelial cell; HPC, hematopoietic progenitor cell; HSC, hematopoietic stem cell; MK, megakaryocyte; NEU, neutrophil; PLT, platelet. For references, see Wang et al.[55]; Liu et al.[56,57]

RELATIONSHIP DISCLOSURE

JA has received grant funding from the British Heart Foundation and is a consultant for Silence Therapeutics; RAA is a consultant for Bristol Myers Squibb, Bayer, and Pfizer; AB has received support from Horizon 2020 FETOpen SilkFusion, NIH, and Novartis; CDB has received grant funding from NHLBI and NIH and is a consultant for Camurus AB; PB has received funding from BioMarin and is a consultant for BioMarin, Pfizer, and the Institute for Medical & Nursing Education; KdW has received grant funding from Pfizer; CD has received grant funding from Haima Therapeutics; MHE is a consultant for Norvartis and Gad Medical; CPMH has received grant funding from the Canadian Institutes for Health Research and is a consultant for Werfen and Diagnostica Stago Inc; FAK has received research support from Bayer, Actelion, the Dutch Thrombosis Association, Actelion, BSCI, The Netherlands Organisation for Health Research and Development, and the Dutch Heart foundation; ZM has received grant funding from CSL Behring; MDN has received grant funding from Haemonetics, Instrumentation Laboratories, and Janssen Pharmaceuticals, is consultant for Haemonetics and Janssen Pharmaceuticals, and serves on the advisory board for Haima Therapeutics; BR has received grant funding from Bayer AG and is a consultant for SOBI and Bayer AG; SS is a consultant for Pfizer, Takeda, and Roche and received support for attending meetings from CSL Behring; DMS is a consultant for BMS-Pfizer, Leo Pharma, Portola Pharmaceuticals, and Servier; KS is a consultant for Novo Nordisk, Chugai Pharmaceutical Co, and Mitsubishi Tanabe Pharma Co; all other authors declare no conflicts of interest.

TWITTER

Robert A. Ariëns @RobertAriens
Beverley J. Hunt @bhwords
Ejaife O. Agbani @DrEjaifeAgbani
Josefin Ahnström @AhnstromJosefin
Robert Ahrends @Ahrends15
Raza Alikhan @dvtdoc
Alice Assinger @PlateletVienna
Zsuzsa Bagoly @bagoly18
Alessandra Balduini @ABalduiniLab
Christopher D. Barrett @ChrisBarrettMD
Paul Batty @paul_batty1
Wee Shian Chan @WeeShianChan
Kerstin Wit @kerstindewit
Cécile Denis @cecile_denis
Renee Eslick @renee_eslick
Hongxia Fu @hongxiaUW
Benoit Ho-Tin-Noé @Team6LVTSINSERM
Frederikus A. Klok @Erik_Klok_MD
Riten Kumar @kumar_riten
Karin Leiderman @karin_leiderman
Matthew D. Neal @macky_neal
William A. E. Parker @TheClotDoc
Roger J. S. Preston @rogerjspreston
Julie Rayes @julierayes
Lara N. Roberts @LaraNRoberts1
Susan Shapiro @shapiro_susie
Deborah M. Siegal @DebSiegal

REFERENCES

1. Gierula M, Ahnström J. Anticoagulant protein S-New insights on interactions and functions. *J Thromb Haemost*. 2020;18:2801-2811.
2. Teraz-Orosz A, Gierula M, Petri A, et al. Laminin G1 residues of protein S mediate its TFPI cofactor function and are competitively regulated by C4BP. *Blood Adv*. 2022;6(2):704-715.
3. Dahlbäck B, Tran S. The preAR2 region (1458-1492) in factor V-Short is crucial for the synergistic TFPIα-cofactor activity with protein S and the assembly of a trimolecular factor Xa-inhibitory complex comprising FV-Short, protein S, and TFPIα. *J Thromb Haemost*. 2022;20(1):58-68.
4. Peng B, Geue S, Coman C, et al. Identification of key lipids critical for platelet activation by comprehensive analysis of the platelet lipidome. *Blood*. 2018;132:e1-e12. doi:10.1182/blood-2017-12-822890
5. Peng B, Kopczynski D, Pratt BS, et al. LipidCreator workbench to probe the lipidomic landscape. *Nat Commun*. 2020;11:2057. doi:10.1038/s41467-020-15960-z
6. Holinstat M. Controlling the Clot: ANXA7 regulates collagen activation of platelet through 12-LOX. *Circ Res*. 2021;121:508-510. doi:10.1161/CIRCRESAHA.121.319736
7. Gauberti M, Martinez de Lizarrondo S, Vivien D. Thrombolytic strategies for ischemic stroke in the thrombectomy era. *J Thromb Haemost*. 2021;19(7):1618-1628.
8. Bagoly Z, Szegedi I, Kalmandi R, Toth NK, Csiba L. Markers of coagulation and fibrinolysis predicting the outcome of acute ischemic stroke thrombolysis treatment: a review of the literature. *Front Neurol*. 2019;10:513.
9. Donkel SJ, Benaddi B, Dippel DWJ, Ten Cate H, de Maat MPM. Prognostic hemostasis biomarkers in acute ischemic stroke. *Arterioscler Thromb Vasc Biol*. 2019;39(3):360-372.
10. Di Buduo CA, Aguilar A, Soprano PM, et al. Latest culture techniques: cracking the secrets of bone marrow to mass-produce erythrocytes and platelets ex vivo. *Haematologica*. 2021;106(4):947-957. doi:10.3324/haematol.2020.262485
11. Di Buduo CA, Wray LS, Tozzi L, et al. Programmable 3D silk bone marrow niche for platelet generation ex vivo and modeling of megakaryopoiesis pathologies. *Blood*. 2015;125(14):2254-2264. doi:10.1182/blood-2014-08-595561
12. Di Buduo CA, Laurent PA, Zaninetti C, et al. Miniaturized 3D bone marrow tissue model to assess response to Thrombopoietin-receptor agonists in patients. *elife*. 2021;10:e58775. doi:10.7554/eLife.58775
13. Arruda VR, Weber J, Samelson-Jones BJ. Gene therapy for inherited bleeding disorders. *Semin Thromb Hemost*. 2021;47(2):161-173. doi:10.1055/s-0041-1722862
14. Rodríguez-Márquez E, Meumann N, Büning H. Adeno-associated virus (AAV) capsid engineering in liver-directed gene therapy. *Expert Opin Biol Ther*. 2021;21(6):749-766. doi:10.1080/14712598.2021.1865303
15. Barbon E, Kawecki C, Marmier S, et al. Development of a dual hybrid AAV vector for endothelial-targeted expression of von Willebrand factor. *Gene Ther*. 2021. doi:10.1038/s41434-020-00218-6
16. Barrett CD, Moore HB, Moore EE, Wang J, Hajizadeh N, Biffl WL, Lottenberg L, Patel PR, Truitt MS, McIntyre R, Talmor DS, Sauaia A, Yaffe MB. STudy of Alteplase for Respiratory failure in SARS-Cov2 COVID-19 (STARS): a vanguard multicenter, rapidly adaptive, pragmatic, randomized, controlled trial. *Chest*. 2022;161(3): 710-727. doi:10.1016/j.chest.2021.09.024

17. Barrett CD, Moore HB, Moore EE, et al. MUlticenter STudy of tissue plasminogen activator use in COVID-19 severe respiratory failure (MUST COVID): a retrospective cohort study. *Res Pract Thromb Haemost*. 2022;6(2): e12669. doi:10.1002/rth2.12669
18. ATTACC Investigators, ACTIV-4a Investigators, REMAP-CAP Investigators, et al. Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19. *N Engl J Med* 2021;385(9): 790-802.
19. Yuki K, Fujiori M, Koutsogiannaki S. COVID-19 pathophysiology: a review. *Clin Immunol*. 2020;215:108427.
20. Gustine JN, Jones D. Immunopathology of hyperinflammation in COVID-19. *Am J Pathol*. 2021;191:4-17.
21. Diamond MS, Kanneganti TD. Innate immunity: the first line of defense against SARS-Cov-2. *Nat Immunol*. 2022;23:165-176. 10.1038/s41590-021-01091-0
22. Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): the task force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). *Eur Heart J*. 2020;41:543-603.
23. van der Pol LM, Tromeur C, Bistervels IM, et al. Pregnancy-adapted YEARS algorithm for diagnosis of suspected pulmonary embolism. *N Engl J Med*. 2019;380(12):1139-1149.
24. Righini M, Robert-Ebadi H, Elias A, et al. Diagnosis of pulmonary embolism during pregnancy: a multicenter prospective management outcome study. *Ann Intern Med*. 2018;169(11):766-773.
25. Alimam, S., Bewley, S., Chappell, L.C, Knight, M., Seed, P., Gray, G., Harrison, CN, Robinson, S.E. (2016) Pregnancy outcomes in myeloproliferative neoplasms: UK prospective cohort study. *Br J Haematol*, 175, 31-36.
26. Maze D, Kazi S, Gupta V, et al. Association of treatments for myeloproliferative neoplasms during pregnancy with birth rates and maternal outcomes: a systematic review and meta-analysis. *JAMA Netw Open*. 2019;2(10):e1912666.
27. Eslick R, Cutts B, Merriman E, et al. HOW Collaborative position paper on the management of thrombocytopenia in pregnancy. *Aust N Z J Obstet Gynaecol*. 2021;61:195-204.
28. Fu H, Jiang Y, Yang D, Scheiflinger F, Wong WP, Springer TA. Flow-induced elongation of von Willebrand factor precedes tension-dependent activation. *Nat Commun*. 2017;8:324. doi:10.1038/s41467-017-00230-2
29. Jiang Y, Fu H, Springer TA, Wong WP. Electrostatic steering enables flow-activated Von Willebrand factor to bind platelet glycoprotein, revealed by single-molecule stretching and imaging. *J Mol Biol*. 2019;431:1380-1396. doi:10.1016/j.jmb.2019.02.014
30. Goldenberg NA, Sochet A, Albisetti M, et al. Consensus-based clinical recommendations and research priorities for anticoagulant thromboprophylaxis in children hospitalized for COVID-19-related illness. *J Thromb Haemost*. 2020;18:3099-3105.
31. Henderson LA, Canna SW, Friedman KG, et al. American College of Rheumatology clinical guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19: version 3. *Arthritis Rheumatol*. 2022;74:e1-e20.
32. Bansal N, Azeka E, Neunert C, et al. Multisystem inflammatory syndrome associated with COVID-19 anti-thrombosis guideline of care for children by action. *Pediatr Cardiol*. 2021;42(7):16235-11639.
33. Tutwiler V, Litvinov RI, Lozhkin AP, et al. Kinetics and mechanics of clot contraction are governed by molecular and cellular blood composition. *Blood*. 2016;127(1):149-159.
34. Peshkova AD, Malyasyov DV, Bredikhin RA, et al. Reduced contraction of blood clots in patients with venous thromboembolism is a possible thrombogenic and embologenic mechanism. *TH Open*. 2018;2(1):e104-e115.
35. Weisel JW, Litvinov RI. Visualizing thrombosis to improve thrombus resolution. *Res Pract Thromb Haemost*. 2021;5(1):38-50.
36. Hisada Y, Mackman N. Update from the laboratory: mechanistic studies of pathways of cancer-associated venous thrombosis using mouse models. *Hematology Am Soc Hematol Educ Program*. 2019;2019(1):182-186.
37. Tawil N, Bassawon R, Meehan B, et al. Glioblastoma cell populations with distinct oncogenic programs release podoplanin as procoagulant extracellular vesicles. *Blood Adv*. 2021;5(6):1682-1694.
38. Hisada Y, Garratt KB, Maqsood A, et al. Plasminogen activator inhibitor 1 and venous thrombosis in pancreatic cancer. *Blood Adv*. 2021;5(2):487-495.
39. Moore EE, Moore HB, Kornblith LZ, et al. Trauma-induced coagulopathy. *Nat Rev Dis Primers*. 2021;7(1):30. doi:10.1038/s41572-021-00264-3
40. Vulliamy P, Kornblith LZ, Kutcher ME, Cohen MJ, Brohi K, Neal MD. Alterations in platelet behavior after major trauma: adaptive or maladaptive? *Platelets*. 2021;32(3):295-304. doi:10.1080/09537104.2020.1718633
41. Plautz WE, Haldeman SH, Dyer MR, et al. Reduced cleavage of von willebrand factor by ADAMTS13 is associated with microangiopathic acute kidney injury following trauma. *Blood Coagul Fibrinolysis*. 2022;33(1):14-24. doi:10.1097/MBC.0000000000001089
42. Parker WAE, Gorog DA, Geisler T, et al. Prevention of stroke in patients with chronic coronary syndromes or peripheral arterial disease. *Eur Heart J Suppl*. 2020;22(Supplement_M):M26-M34.
43. Roberts LN, Durkin M, Arya R. Annotation: developing a national programme for VTE prevention. *Br J Haematol*. 2017;178(1):162-170.
44. NHS Digital. NHS Outcomes Framework Indicators dataset. 5.1 Deaths from venous thromboembolism (VTE) related events within 90days post hospital discharge. 2021. https://digital.nhs.uk/data-and-information/publications/statistical/nhs-outcomes-framework/february-2021/domain-5-treating-and-caring-for-people-in-a-safe-environment-and-protecting-them-from-avoidable-harm-nof/5.1-deaths-from-venous-thromboembolism-vte-related-events-within-90-days-post-discharge-from-hospital
45. Tosetto A, Rocca B, Petrucci G, et al. Association of platelet thromboxane inhibition by low-dose aspirin with platelet count and cytoreductive therapy in essential thrombocythemia. *Clin Pharm Ther*. 2022;111:939-949.
46. Rocca B, Tosetto A, Betti S, et al. A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia. *Blood*. 2020;136(2):171-182.
47. Petrucci G, Zaccardi F, Giaretta A, et al. Obesity is associated with impaired responsiveness to once-daily low-dose aspirin and in vivo platelet activation. *J Thromb Haemost*. 2019;17(6):885-895.
48. Xu Y, Siegal DM. Anticoagulant-assoiated gastrointestinal bleeding: framework for decisions about whether, when and how to resume anticoagulants. *J Thromb Haemost*. 2021;19:2383-2393.
49. Sousa LP, Alessandri AL, Pinho V, Teixeira MM. Pharmacological strategies to resolve acute inflammation. *Curr Opin Pharmacol*. 2013;13(4):625-631.
50. Sugimoto MA, Ribeiro ALC, Costa BRC, et al. Plasmin and plasminogen induce macrophage reprogramming and regulate key steps of inflammation resolution via annexin A1. *Blood*. 2017;129(21):2896-2907.
51. Vago JP, Sugimoto MA, Lima KM, et al. Plasminogen and the plasminogen receptor, Plg-R_{KT}, regulate macrophage phenotypic, and functional changes. *Front Immunol*. 2019;10:1458.
52. Original art by Rahimeen Qasim Ali, Grade 9 student, Presentation Convent School, Lal Kurti, Rawalpindi, Pakistan.
53. Butt MA. Women's health problems in Pakistan. *Middle East J Fam Med*. 2004;2(2).
54. UN report on Pakistani women health matters. https://www.dawn.com/.news/1389532

55. Wang H, He J, Xu C, et al. Decoding human megakaryocyte development. *Cell Stem Cell*. 2021;28(3):535-549.
56. Liu C, Wu D, Xia M, et al. Characterization of cellular heterogeneity and an immune subpopulation of human megakaryocytes. *Adv Sci (Weinh)*. 2021;8(15):e2100921.
57. Liu C, Huang B, Wang H, Zhou J. The heterogeneity of megakaryocytes and platelets and implications for ex vivo platelet generation. *Stem Cells Transl Med*. 2021;10(12):1614-1620.

How to cite this article: Ariëns RA, Hunt BJ, Agbani EO, et al. Illustrated State-of-the-Art Capsules of the ISTH 2022 Congress. *Res Pract Thromb Haemost*. 2022;6:e12747. doi: 10.1002/rth2.12747